KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Assets Average (2016 - 2025)

Historic Assets Average for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $2.1 billion.

  • Halozyme Therapeutics' Assets Average rose 459.08% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 459.08%. This contributed to the annual value of $1.9 billion for FY2024, which is 620.92% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Assets Average stood at $2.1 billion for Q3 2025, which was up 459.08% from $2.1 billion recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Assets Average ranged from a high of $2.1 billion in Q3 2025 and a low of $773.3 million during Q1 2021
  • For the 5-year period, Halozyme Therapeutics' Assets Average averaged around $1.7 billion, with its median value being $1.8 billion (2023).
  • Its Assets Average has fluctuated over the past 5 years, first surged by 11039.28% in 2021, then plummeted by 216.19% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Assets Average (Quarter) stood at $1.1 billion in 2021, then soared by 61.85% to $1.9 billion in 2022, then dropped by 2.16% to $1.8 billion in 2023, then grew by 15.32% to $2.1 billion in 2024, then grew by 2.24% to $2.1 billion in 2025.
  • Its Assets Average was $2.1 billion in Q3 2025, compared to $2.1 billion in Q2 2025 and $2.1 billion in Q1 2025.